SALIM VIRANI to Cost-Benefit Analysis
This is a "connection" page, showing publications SALIM VIRANI has written about Cost-Benefit Analysis.
Connection Strength
0.627
-
Improving adherence to cardiovascular guidelines: realistic transition from paper to patient. Expert Rev Cardiovasc Ther. 2020 Jan; 18(1):41-51.
Score: 0.142
-
Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019 Sep - Oct; 62(5):406-413.
Score: 0.140
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.132
-
Favorable Modifiable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs Among Cancer Patients: The 2012-2013 Medical Expenditure Panel Survey. J Am Heart Assoc. 2018 04 23; 7(9).
Score: 0.126
-
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol. 2017 12 01; 2(12):1369-1374.
Score: 0.031
-
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
Score: 0.030
-
Favorable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs and Resource Utilization: The 2012 Medical Expenditure Panel Survey. Circ Cardiovasc Qual Outcomes. 2016 Mar; 9(2):143-53.
Score: 0.027